Survival outcomes in iron chelated and non-chelated patients with lower-risk myelodysplastic syndromes: Review and pooled analysis of observational studies.
Center for Health Outcomes and PharmacoEconomic Research, University of Arizona, Tucson, AZ, USA; University of Arizona Cancer Center, Tucson, AZ, USA; Department of Pharmacy Practice and Science, College of Pharmacy, University of Arizona, Tucson, AZ, USA; Department of Family and Community Medicine, College of Medicine, University of Arizona, Tucson, AZ, USA; Matrix45, Tucson, AZ, USA. Electronic address: abraham@pharmacy.arizona.edu.
Ivo
I
Abraham
Center for Health Outcomes and PharmacoEconomic Research, University of Arizona, Tucson, AZ, USA; King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia.
Majed Al
MA
Yami
H. Lee Moffitt Cancer Center, Tampa, FL, USA.
Seongseok
S
Yun
College of Nursing, Catholic University of Korea, Seoul, Republic of Korea.
Hee-Ju
HJ
Kim
H. Lee Moffitt Cancer Center, Tampa, FL, USA.
Nicole D
ND
Vincelette
University of Arizona Cancer Center, Tucson, AZ, USA; Department of Pharmacy Practice and Science, College of Pharmacy, University of Arizona, Tucson, AZ, USA.
Ali
A
McBride
Matrix45, Tucson, AZ, USA.
Karen
K
MacDonald
D001803:Blood Transfusion; D015913:Chelation Therapy / Q000379:methods; D006801:Humans; D007502:Iron Chelating Agents / Q000627:therapeutic use*; D019190:Iron Overload / Q000188:drug therapy / Q000209:etiology; D009190:Myelodysplastic Syndromes / Q000401:mortality* / Q000628:therapy*; D064887:Observational Studies as Topic
D007502:Iron Chelating Agents